secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2023-02-08T23:59:59+00:00
Accession:  0001628280-23-002764
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Q4/FY2022: revenue $64.5M/$254.4M, net income down; patent litigation continues
--------------------------------------------------------------------------------

- Q4 total net product sales $64.5M (-5% YoY); FY2022 sales $254.4M (-5% YoY). Net income Q4 $6.9M ($0.12 diluted) vs $7.1M; FY net income $6.3M ($0.11) down from $33.2M ($0.58) in 2021.
- HETLIOZ sales Q4 $40.1M (-9% YoY) due to reimbursement challenges; Fanapt $24.4M (+2% YoY).
- Teva launched generic HETLIOZ at risk; appeal in patent litigation scheduled for March 14, 2023. New patent infringement lawsuits filed against Teva and Apotex.
- Plans to submit NDA for tradipitant (gastroparesis) and sNDA for Fanapt (bipolar I disorder) in H1 2023. Phase III motion sickness results expected mid-2023.
- No 2023 financial guidance provided due to uncertainties from HETLIOZ patent litigation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828023002764/0001628280-23-002764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828023002764/vnda-20230208.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-002764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer